Home » Posts tagged with » bamlanivimab
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA
The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly and Company (Lilly) for the treatment of mild to moderate Covid-19. Bamlanivimab has been authorized to be used in adults and pediatric patients, aged 12 years and older with a […]
Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt
October 29, 2020 No Comment
Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, an investigational neutralizing antibody for the treatment of Covid-19. LY-CoV555 is the first antibody candidate to come out from Lilly’s collaboration with AbCellera Biologics, which was announced in March this […]
Continue reading …
Business News Today
- Chinese lifestyle product retailer MINISO opens new store in Madrid
- Unilever to acquire Los Angeles-based SmartyPants Vitamins
- Bega Cheese to acquire Lion Dairy & Drinks for $412m
- Nestlé to sell Yinlu peanut milk and canned rice porridge businesses in China
- TEXRail extension project : Trinity Metro selects AECOM as project consultant
- Castle Mountain Gold Mine California : Equinox Gold achieves commercial production
- McCormick to acquire Mexican hot sauce brand Cholula Hot Sauce
- Elliott Advisors offers to take over Swiss food company Aryzta for CHF0.8 per share
- US challenger bank Current raises $131m in Series C round
- HelloFresh to acquire US meal delivery service provider Factor75
